Merck (MRK) Stock Surges on Breakthrough Lung Cancer Combination Therapy Results

Merck (MRK) stock jumped 4% after Phase 3 trial showed Keytruda plus sac-TMT achieved 70% response rate in lung cancer patients, cutting progression risk by 65%.

The post Merck (MRK) Stock Surges on Breakthrough Lung Cancer Combination Therapy Results appeared first on Blockonomi.